Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.66 |
| ▸ | EGFR | P00533 | 9/20 | 0.66 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.66 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.66 |
| ▸ | FECH | P22830 | 1/20 | 0.61 |
| ▸ | CDK8 | P49336 | 1/20 | 0.61 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.61 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24832693 | 0.90 | ERBB2 (0.68) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL4866251 | 0.89 | EGFR (0.67) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL29888726 | 0.89 | ERBB2 (0.67) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL24569330 | 0.89 | ERBB2 (0.67) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL5251879 | 0.88 | ERBB2 (0.66) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL2702250 | 0.88 | ERBB2 (0.66) | ERBB2EGFRERBB3ERBB4FECH | |
| Hydrochloric Acid SCHEMBL214923 | 0.87 | ERBB2 (0.64) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL6017285 | 0.87 | ERBB2 (0.51) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL4463961 | 0.86 | ERBB2 (0.63) | ERBB2EGFRERBB3ERBB4FECH | |
| SCHEMBL4471160 | 0.84 | EGFR (0.70) | ERBB2EGFRERBB3ERBB4FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | ERBB2 2/4885EGFR 15/4885ERBB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.